Supplementary Information for:

Dynamic Clinical Success Rates for Drugs in the 21st Century

Ying Zhou^{1,†}, Yintao Zhang^{1,†}, Zhen Chen^{1,†}, Shijie Huang¹, Yinghong Li¹, Jianbo Fu², Hongning Zhang¹, Donghai Zhao¹, Xichen Lian¹, Yuan Zhou¹, Xinyi Shen³, Yunqing Qiu¹, Lianyi Han⁴, Feng Zhu^{1,*}

¹ College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.


² Centre for Clinical Research, Helmholtz Centre for Infection Research, Hannover 30625, Germany.

³ Yale School of Public Health, Yale University, New Haven 06510, United States.


⁴ Greater Bay Area Institute of Precision Medicine, Fudan University, Shanghai 315211, China.

^{*}Corresponding to Prof. Feng Zhu, Email: zhufeng@zju.edu.cn


[†]These authors contributed equally: Ying Zhou, Yintao Zhang, Zhen Chen.




Supplementary Figure S1. The dynamic *clinical success rate* (ClinSR) evaluated based on the CTPs of *oncology* (CACER) collected for this study. A nine-year time-window was adopted here to facilitate the assessments of ClinSRs, which provided a drug adequate period of time to reach its final fate, and a total of fifteen time-windows (from 2001-2009 to 2015-2023, inclusive) were then assessed. The *phase success rates* (PSRs) of P1SR, P2SR and P3SR were shown using bars in blue, yellow and red, respectively. The dark line gave the dynamic variation in *overall success rate* (OSR). P1SR: Phase 1 success rate; P2SR: Phase 2 success rate; P3SR: Phase 3 success rate.




Supplementary Figure S2. Dynamic *clinical success rate* (ClinSR) assessed using the CTPs of *neurological disease* (NEURO) collected by this study. A nine-year time-window was used here to facilitate the assessments of ClinSRs, which provided a drug adequate period of time to reach its final fate, and a total of fifteen time-windows (from 2001-2009 to 2015-2023, inclusive) were then assessed. The *phase success rates* (PSRs) of P1SR, P2SR and P3SR were shown using bars in blue, yellow and red, respectively. The dark line gave the dynamic variation in *overall success rate* (OSR). P1SR: Phase 1 success rate; P2SR: Phase 2 success rate; P3SR: Phase 3 success rate.




Supplementary Figure S3. Dynamic *clinical success rate* (ClinSR) assessed using the CTPs of *infectious/parasitic disease* (INFEC) collected for this study. A nine-year time-window was used to facilitate the assessments of ClinSRs, which provided a drug adequate period of time to reach its final fate, and a total of fifteen time-windows (from 2001-2009 to 2015-2023, inclusive) were then assessed. The *phase success rates* (PSRs) of P1SR, P2SR and P3SR were shown using bars in blue, yellow and red, respectively. The dark line gave the dynamic variation in *overall success rate* (OSR). P1SR: Phase 1 success rate; P2SR: Phase 2 success rate; P3SR: Phase 3 success rate.




Supplementary Figure S4. Dynamic *clinical success rate* (ClinSR) assessed using the CTPs of *blood/blood-forming organs disease* (BLOOD) in this study. A nine-year time-window was used to facilitate the assessments of ClinSRs, which provided a drug adequate period of time to reach its final fate, and a total of fifteen time-windows (from 2001-2009 to 2015-2023, inclusive) were then assessed. The *phase success rates* (PSRs) of P1SR, P2SR and P3SR were shown using bars in blue, yellow and red, respectively. The dark line gave the dynamic variation in *overall success rate* (OSR). P1SR: Phase 1 success rate; P2SR: Phase 2 success rate; P3SR: Phase 3 success rate.




Supplementary Figure S5. Dynamic *clinical success rate* (ClinSR) assessed using the CTPs of *immune system disease* (IMMNU) collected by this study. A nine-year time-window was adopted to facilitate the assessments of ClinSRs, which provided a drug adequate period of time to reach its final fate, and a total of fifteen time-windows (from 2001-2009 to 2015-2023, inclusive) were then assessed. The *phase success rates* (PSRs) of P1SR, P2SR and P3SR were shown using bars in blue, yellow and red, respectively. The dark line gave the dynamic variation in *overall success rate* (OSR). P1SR: Phase 1 success rate; P2SR: Phase 2 success rate; P3SR: Phase 3 success rate.




Supplementary Figure S6. Dynamic *clinical success rate* (ClinSR) assessed using the CTPs of *endocrine, nutritional or metabolic disease* (METAB). A nine-year time-window was used here to facilitate the assessments of ClinSRs, which provided a drug adequate period of time to reach its final fate, and a total of fifteen time-windows (from 2001-2009 to 2015-2023, inclusive) were then assessed. The *phase success rates* (PSRs) of P1SR, P2SR and P3SR were shown using bars in blue, yellow and red, respectively. The dark line gave the dynamic variation in *overall success rate* (OSR). P1SR: Phase 1 success rate; P2SR: Phase 2 success rate; P3SR: Phase 3 success rate.




Supplementary Figure S7. Dynamic *clinical success rate* (ClinSR) assessed using the CTPs of *visual system disease* (VISAL) collected for this study. A nine-year time-window was used here to facilitate the assessments of ClinSRs, which provided a drug adequate period of time to reach its final fate, and a total of fifteen time-windows (from 2001-2009 to 2015-2023, inclusive) were then assessed. The *phase success rates* (PSRs) of P1SR, P2SR and P3SR were shown using bars in blue, yellow and red, respectively. The dark line gave the dynamic variation in *overall success rate* (OSR). P1SR: Phase 1 success rate; P2SR: Phase 2 success rate; P3SR: Phase 3 success rate.




Supplementary Figure S8. Dynamic *clinical success rate* (ClinSR) assessed using the CTPs of *circulatory system disease* (CIRCU) collected for this study. A nine-year time-window was used to facilitate the assessments of ClinSRs, which provided a drug adequate period of time to reach its final fate, and a total of fifteen time-windows (from 2001-2009 to 2015-2023, inclusive) were then assessed. The *phase success rates* (PSRs) of P1SR, P2SR and P3SR were shown using bars in blue, yellow and red, respectively. The dark line gave the dynamic variation in *overall success rate* (OSR). P1SR: Phase 1 success rate; P2SR: Phase 2 success rate; P3SR: Phase 3 success rate.




Supplementary Figure S9. Dynamic *clinical success rate* (ClinSR) assessed using the CTPs of *respiratory system disease* (RESPR) collected for this study. A nine-year time-window was used to facilitate the assessments of ClinSRs, which provided a drug adequate period of time to reach its final fate, and a total of fifteen time-windows (from 2001-2009 to 2015-2023, inclusive) were then assessed. The *phase success rates* (PSRs) of P1SR, P2SR and P3SR were shown using bars in blue, yellow and red, respectively. The dark line gave the dynamic variation in *overall success rate* (OSR). P1SR: Phase 1 success rate; P2SR: Phase 2 success rate; P3SR: Phase 3 success rate.




Supplementary Figure S10. Dynamic *clinical success rate* (ClinSR) evaluated using the CTPs of *digestive system disease* (DIGST) collected for this study. A nine-year time-window was used to facilitate the assessments of ClinSRs, which provided a drug adequate period of time to reach its final fate, and a total of fifteen time-windows (from 2001-2009 to 2015-2023, inclusive) were then assessed. The *phase success rates* (PSRs) of P1SR, P2SR and P3SR were shown using bars in blue, yellow and red, respectively. The dark line gave the dynamic variation in *overall success rate* (OSR). P1SR: Phase 1 success rate; P2SR: Phase 2 success rate; P3SR: Phase 3 success rate.




Supplementary Figure S11. The dynamic *clinical success rate* (ClinSR) assessed based on the CTPs of *skin disease* (SKINS) gathered in this study. A nine-year time-window was adopted here to facilitate the assessments of ClinSRs, which provided a drug adequate period of time to reach its final fate, and a total of fifteen time-windows (from 2001-2009 to 2015-2023, inclusive) were then assessed. The *phase success rates* (PSRs) of P1SR, P2SR and P3SR were shown using bars in blue, yellow and red, respectively. The dark line gave the dynamic variation in *overall success rate* (OSR). P1SR: Phase 1 success rate; P2SR: Phase 2 success rate; P3SR: Phase 3 success rate.




Supplementary Figure S12. Dynamic *clinical success rate* (ClinSR) measured by the CTPs of *musculoskeletal system/connective tissue disease* (MUSKE). A nine-year time-window was used to facilitate the assessments of ClinSRs, which provided a drug adequate period of time to reach its final fate, and a total of fifteen time-windows (from 2001-2009 to 2015-2023, inclusive) were then assessed. The *phase success rates* (PSRs) of P1SR, P2SR and P3SR were shown using bars in blue, yellow and red, respectively. The dark line gave the dynamic variation in *overall success rate* (OSR). P1SR: Phase 1 success rate; P2SR: Phase 2 success rate; P3SR: Phase 3 success rate.




Supplementary Figure S13. Dynamic *clinical success rate* (ClinSR) measured by the CTPs of *genitourinary and sexual related disease* (GENIT). A nine-year time-window was adopted here to facilitate the assessments of ClinSRs, which provided a drug adequate period of time to reach its final fate, and a total of fifteen time-windows (from 2001-2009 to 2015-2023, inclusive) were then assessed. The *phase success rates* (PSRs) of P1SR, P2SR and P3SR were shown using bars in blue, yellow and red, respectively. The dark line gave the dynamic variation in *overall success rate* (OSR). P1SR: Phase 1 success rate; P2SR: Phase 2 success rate; P3SR: Phase 3 success rate.




Supplementary Figure S14. The dynamic *clinical success rate* (ClinSR) measured by the CTPs of *other diseases* (OTHER) collected for this study. A nine-year time-window was adopted here to facilitate the assessments of ClinSRs, which provided a drug adequate period of time to reach its final fate, and a total of fifteen time-windows (from 2001-2009 to 2015-2023, inclusive) were then assessed. The *phase success rates* (PSRs) of P1SR, P2SR and P3SR were shown using bars in blue, yellow and red, respectively. The dark line gave the dynamic variation in *overall success rate* (OSR). P1SR: Phase 1 success rate; P2SR: Phase 2 success rate; P3SR: Phase 3 success rate.




Supplementary Figure S15. Hierarchical clustering of fifteen different disease classes based on their *phase* 1 *success rate* (P1SR) across fifteen consecutive time-windows. The darker the blue color, the higher the success rate of clinical drug development in the corresponding time-window and the corresponding indication. All: all disease indication; INFEC: infectious/parasitic disease; BLOOD: blood/blood-forming organs disease; CACER: oncology; CIRCU: circulatory system disease; DIGST: digestive system disease; SKINS: skin disease; METAB: endocrine, nutritional or metabolic disease; RESPR: respiratory system disease; MUSKE: musculoskeletal system and connective tissue disease; GENIT: genitourinary and sexual related disease; NEURO: neurology; VISAL: visual system disease; IMMUN: immune system disease; OTHER: Other disease.




Supplementary Figure S16. Hierarchical clustering of fifteen different disease classes based on the *phase 2 success rate* (P2SR) across fifteen consecutive time-windows. The darker the yellow color, the higher the success rate of clinical drug development in the corresponding time-window and the corresponding indication. All: all disease indication; INFEC: infectious/parasitic disease; BLOOD: blood/blood-forming organs disease; CACER: oncology; CIRCU: circulatory system disease; DIGST: digestive system disease; SKINS: skin disease; METAB: endocrine, nutritional or metabolic disease; RESPR: respiratory system disease; MUSKE: musculoskeletal system and connective tissue disease; GENIT: genitourinary and sexual related disease; NEURO: neurology; VISAL: visual system disease; IMMUN: immune system disease; OTHER: Other disease.




Supplementary Figure S17. Hierarchical clustering of fifteen different disease classes based on their *phase 3 success rate* (P3SR) across fifteen consecutive time-windows. The darker the red color, the higher the success rate of clinical drug development in the corresponding time-window and the corresponding indication. All: all disease indication; INFEC: infectious/parasitic disease; BLOOD: blood/blood-forming organs disease; CACER: oncology; CIRCU: circulatory system disease; DIGST: digestive system disease; SKINS: skin disease; METAB: endocrine, nutritional or metabolic disease; RESPR: respiratory system disease; MUSKE: musculoskeletal system and connective tissue disease; GENIT: genitourinary and sexual related disease; NEURO: neurology; VISAL: visual system disease; IMMUN: immune system disease; OTHER: Other disease.




Supplementary Figure S18. The dynamic *clinical success rate* (ClinSR) measured by the CTPs of *small molecular drug* (SMD) collected for this study. A nine-year time-window was used here to facilitate the assessments of ClinSRs, which provided a drug adequate period of time to reach its final fate, and a total of fifteen time-windows (from 2001-2009 to 2015-2023, inclusive) were then assessed. The *phase success rates* (PSRs) of P1SR, P2SR and P3SR were shown using bars in blue, yellow and red, respectively. The dark line gave the dynamic variation in *overall success rate* (OSR). P1SR: Phase 1 success rate; P2SR: Phase 2 success rate; P3SR: Phase 3 success rate.



Supplementary Figure S19. The dynamic *clinical success rate* (ClinSR) measured by the CTPs of *antibody-related drug* (ARD) collected for this study. A nine-year time-window was used here to facilitate the assessments of ClinSRs, which provided a drug adequate period of time to reach its final fate, and a total of fifteen time-windows (from 2001-2009 to 2015-2023, inclusive) were then assessed. The *phase success rates* (PSRs) of P1SR, P2SR and P3SR were shown using bars in blue, yellow and red, respectively. The dark line gave the dynamic variation in *overall success rate* (OSR). P1SR: Phase 1 success rate; P2SR: Phase 2 success rate; P3SR: Phase 3 success rate.



Supplementary Figure S20. The dynamic *clinical success rate* (ClinSR) measured by the CTPs of *protein & peptide drug* (PPD) collected for this study. A nine-year time-window was used here to facilitate the assessments of ClinSRs, which provided a drug adequate period of time to reach its final fate, and a total of fifteen time-windows (from 2001-2009 to 2015-2023, inclusive) were then assessed. The *phase success rates* (PSRs) of P1SR, P2SR and P3SR were shown using bars in blue, yellow and red, respectively. The dark line gave the dynamic variation in *overall success rate* (OSR). P1SR: Phase 1 success rate; P2SR: Phase 2 success rate; P3SR: Phase 3 success rate.



Supplementary Figure S21. The dynamic *clinical success rate* (ClinSR) assessed based on the CTPs of *other drug* (OTH) collected for this study. A nine-year time-window was adopted here to facilitate the assessments of ClinSRs, which provided a drug adequate period of time to reach its final fate, and a total of fifteen time-windows (from 2001-2009 to 2015-2023, inclusive) were then assessed. The *phase success rates* (PSRs) of P1SR, P2SR and P3SR were shown using bars in blue, yellow and red, respectively. The dark line gave the dynamic variation in *overall success rate* (OSR). P1SR: Phase 1 success rate; P2SR: Phase 2 success rate; P3SR: Phase 3 success rate.

Supplementary Table S1. The representative studies previously published that related to the analysis of clinical success rate (ClinSR) of drugs.

(a) Representative studies analyzing the success rates for the whole industry	
Approval success rates of drug candidates based on target, action, modality, and their combinations	Clin Transl Sci. 2021; 14: 1113
Trends in clinical success rates and therapeutic focus	Nat Rev Drug Discov. 2019; 18: 495
Estimation of clinical trial success rates and related parameters	Biostatistics. 2019; 20: 273
Trends in clinical success rates	Nat Rev Drug Discov. 2016; 15: 379
Clinical development success rates for investigational drugs	Nat Biotechnol. 2014; 32: 40
Trends in risks associated with new drug development success rates for investigational drugs	Clin Pharmacol Ther. 2010; 87: 272
Can the pharmaceutical industry reduce attrition rates	Nat Rev Drug Discov. 2004; 3: 711
(b) Representative studies analyzing the success rates for certain disease class	
Development times and approval success rates for drugs to treat infectious diseases	Clin Pharmacol Ther. 2020; 107: 324
Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18	Lancet Oncol. 2019; 20: e619
Lessons learned from two decades of anticancer drugs	Trends Pharmacol Sci. 2017; 38: 852
A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial	J Immunother Cancer. 2015; 3:48
Clinical approval success rates for investigational cancer drugs	Clin Pharmacol Ther. 2013; 94: 329
Development trends for new cancer therapeutics and vaccines	Drug Discov Today. 2008; 13: 30
(c) Representative studies analyzing the success rates for certain individual disease	
The wider perspective twenty years of clinical trials in myelodysplastic syndromes	Br J Haematol. 2022; 196: 329

J Alzheimers Dis. 2022; 87:83
J Parkinsons Dis. 2021;11: 421
Hematol Oncol. 2021; 39: 105
Nat Rev Drug Discov. 2019; 18: 658
Cancer. 2017; 123: 4672
Respiration. 2016; 91: 79
Mult Scler Relat Disord. 2016; 5: 8
CJG Hepatol. 2016; 2016: 6260271
Obes Rev. 2015; 16: 707
Alzheimers Res Ther. 2014; 6:37
J Pharm Pharm Sci. 2011; 14: 227
J Pharm Pharm Sci. 2010;13: 191
Drug Discov Today. 2022; 27: 697
Drug Discov Today. 2021; 26: 308

Supplementary Table S2. The *phase 1 success rates* (P1SRs) for all CTPs and the CTPs of particular disease class (a total of 14 classes defined by WHO ICD-11) calculated across fifteen nine-year time-windows. All: all diseases; INFEC: Infectious/parasitic disease; CACER: Oncology; BLOOD: Blood/blood-forming organs disease; IMMUN: Immune system disease; METAB: Endocrine, nutritional or metabolic disease; NEURO: Neurology; VISAL: Visual system disease; CIRCU: Circulatory system disease; RESPR: Respiratory system disease; DIGST: Digestive system disease; SKINS: Skin disease; MUSKE: Musculoskeletal system/connective tissue disease; GENIT: Genitourinary and sexual related disease; OTHER: Other disease.

Disease Class	2001 -2009	2002 -2010	2003 -2011	2004 -2012	2005 -2013	2006 -2014	2007 -2015	2008 -2016	2009 -2017	2010 -2018	2011 -2019	2012 -2020	2013 -2021	2014 -2022	2015 -2023
A11	69.7%	69.4%	65.6%	63.7%	59.4%	56.9%	55.8%	54.2%	52.9%	51.5%	50.7%	48.0%	49.8%	51.0%	51.3%
01 INFEC	76.2%	73.9%	64.8%	59.1%	51.0%	48.0%	48.4%	46.5%	43.0%	40.7%	42.5%	39.6%	47.5%	46.7%	44.3%
02 CACER	67.8%	67.8%	65.0%	64.3%	59.8%	56.2%	53.4%	51.8%	49.8%	46.4%	44.2%	40.0%	40.2%	40.0%	39.1%
03 BLOOD	92.9%	93.8%	81.0%	82.6%	75.9%	64.9%	70.3%	61.5%	63.0%	55.8%	58.2%	62.5%	57.4%	64.8%	76.4%
04 IMMUN	70.0%	85.0%	73.9%	61.8%	56.8%	58.5%	58.2%	57.6%	64.9%	62.5%	55.8%	57.1%	66.0%	67.2%	69.8%
05 METAB	69.4%	68.1%	57.5%	48.6%	47.3%	46.1%	43.9%	42.4%	42.5%	43.5%	44.9%	44.4%	50.3%	52.6%	55.9%
06 NEURO	74.2%	73.6%	66.2%	61.7%	58.9%	57.0%	58.1%	57.8%	56.8%	57.0%	59.2%	58.3%	58.7%	62.1%	62.7%
07 VISAL	73.9%	71.4%	62.9%	66.7%	68.0%	69.5%	68.9%	73.7%	70.7%	74.0%	68.8%	62.0%	62.5%	61.0%	59.0%
08 CIRCU	66.7%	58.3%	60.0%	67.4%	62.5%	64.1%	67.1%	66.7%	70.7%	71.8%	70.7%	67.9%	65.8%	65.9%	63.4%
09 RESPR	74.4%	70.0%	68.3%	68.4%	59.4%	60.8%	61.6%	58.5%	56.4%	57.4%	57.6%	55.6%	56.8%	60.2%	64.1%

10 DIGST	60.9%	63.6%	75.0%	72.6%	72.3%	66.7%	69.6%	65.8%	62.1%	65.6%	66.1%	67.4%	71.7%	75.2%	71.8%
11 SKINS	57.7%	74.2%	73.5%	69.2%	60.8%	58.7%	62.9%	65.7%	62.6%	65.1%	64.5%	66.1%	66.4%	68.5%	70.6%
12 MUSKE	83.3%	68.3%	68.8%	66.7%	61.9%	58.3%	62.5%	58.5%	58.0%	56.7%	57.6%	61.6%	68.2%	62.6%	65.1%
13 GENIT	91.7%	92.9%	82.4%	73.9%	75.0%	76.5%	79.4%	75.8%	69.7%	78.1%	75.9%	66.7%	77.4%	75.8%	70.6%
14 OTHER	56.3%	50.0%	57.7%	58.3%	64.7%	65.2%	59.2%	55.4%	59.3%	62.1%	68.6%	65.4%	65.5%	69.9%	75.0%

Supplementary Table S3. The *phase 2 success rates* (P2SRs) for all CTPs and the CTPs of particular disease class (a total of 14 classes defined by WHO ICD-11) calculated across fifteen nine-year time-windows. All: all diseases; INFEC: Infectious/parasitic disease; CACER: Oncology; BLOOD: Blood/blood-forming organs disease; IMMUN: Immune system disease; METAB: Endocrine, nutritional or metabolic disease; NEURO: Neurology; VISAL: Visual system disease; CIRCU: Circulatory system disease; RESPR: Respiratory system disease; DIGST: Digestive system disease; SKINS: Skin disease; MUSKE: Musculoskeletal system/connective tissue disease; GENIT: Genitourinary and sexual related disease; OTHER: Other disease.

Disease Class	2001 -2009	2002 -2010	2003 -2011	2004 -2012	2005 -2013	2006 -2014	2007 -2015	2008 -2016	2009 -2017	2010 -2018	2011 -2019	2012 -2020	2013 -2021	2014 -2022	2015 -2023
A11	35.8%	32.8%	31.1%	28.3%	26.3%	24.2%	24.1%	23.3%	23.2%	23.1%	23.8%	22.2%	23.6%	25.1%	26.0%
01 INFEC	46.9%	44.7%	44.6%	41.5%	37.8%	34.1%	34.8%	32.5%	31.2%	28.4%	27.0%	22.1%	28.9%	34.6%	30.4%
02 CACER	29.1%	27.5%	26.9%	23.3%	21.7%	19.3%	18.5%	17.4%	16.6%	15.9%	16.8%	15.5%	16.2%	16.7%	18.1%
03 BLOOD	66.7%	58.8%	50.0%	47.1%	42.1%	45.5%	48.1%	51.7%	52.2%	55.1%	56.8%	51.1%	51.1%	47.9%	48.9%
04 IMMUN	58.3%	57.7%	53.6%	48.4%	44.7%	42.6%	35.5%	33.3%	35.6%	35.6%	38.1%	32.1%	32.2%	36.5%	35.3%
05 METAB	50.5%	41.0%	34.0%	31.7%	30.1%	29.3%	32.6%	33.3%	32.6%	34.6%	36.0%	35.7%	35.9%	36.0%	37.3%
06 NEURO	33.7%	30.9%	28.6%	25.9%	24.1%	22.7%	22.9%	24.9%	24.9%	24.9%	25.7%	25.4%	25.2%	27.5%	28.3%
07 VISAL	54.2%	50.0%	47.4%	38.6%	34.8%	33.7%	33.7%	33.0%	31.1%	30.9%	29.9%	29.0%	33.3%	35.9%	35.7%
08 CIRCU	37.8%	34.0%	27.6%	27.1%	29.4%	28.0%	24.3%	21.4%	22.5%	24.0%	22.0%	20.6%	21.4%	22.1%	22.1%
09 RESPR	29.2%	25.8%	26.1%	24.3%	23.8%	20.9%	20.3%	19.9%	19.4%	20.0%	19.6%	17.6%	22.2%	24.2%	23.4%

10 DIGST	38.5%	34.4%	33.8%	30.9%	27.9%	24.4%	24.1%	19.7%	22.8%	26.1%	26.6%	24.8%	26.0%	28.9%	28.8%
11 SKINS	28.6%	31.5%	29.2%	24.7%	21.0%	21.1%	23.2%	22.4%	24.4%	26.3%	25.9%	24.3%	26.6%	28.5%	30.2%
12 MUSKE	38.2%	38.1%	36.0%	36.3%	33.0%	30.9%	28.5%	26.6%	27.7%	27.2%	28.2%	24.8%	26.8%	29.0%	32.5%
13 GENIT	39.3%	30.6%	28.2%	29.4%	28.8%	29.2%	26.1%	29.0%	30.0%	27.9%	31.0%	30.2%	25.3%	25.9%	29.9%
14 OTHER	56.8%	39.6%	42.6%	36.9%	30.7%	26.7%	32.1%	29.8%	29.2%	28.2%	31.3%	29.6%	29.9%	29.7%	30.9%

Supplementary Table S4. The *phase 3 success rates* (P3SRs) for all CTPs and the CTPs of particular disease class (a total of 14 classes defined by WHO ICD-11) calculated across fifteen nine-year time-windows. All: all diseases; INFEC: Infectious/parasitic disease; CACER: Oncology; BLOOD: Blood/blood-forming organs disease; IMMUN: Immune system disease; METAB: Endocrine, nutritional or metabolic disease; NEURO: Neurology; VISAL: Visual system disease; CIRCU: Circulatory system disease; RESPR: Respiratory system disease; DIGST: Digestive system disease; SKINS: Skin disease; MUSKE: Musculoskeletal system/connective tissue disease; GENIT: Genitourinary and sexual related disease; OTHER: Other disease.

Disease Class	2001 -2009	2002 -2010	2003 -2011	2004 -2012	2005 -2013	2006 -2014	2007 -2015	2008 -2016	2009 -2017	2010 -2018	2011 -2019	2012 -2020	2013 -2021	2014 -2022	2015 -2023
A11	54.6%	51.5%	48.8%	44.0%	41.6%	41.2%	40.7%	38.8%	39.4%	40.0%	40.1%	39.0%	40.8%	40.2%	39.2%
01 INFEC	60.7%	60.7%	55.7%	50.0%	41.8%	45.7%	46.8%	44.6%	41.0%	42.1%	38.2%	36.3%	37.4%	31.1%	22.8%
02 CACER	40.9%	38.2%	38.6%	37.5%	39.3%	37.5%	39.8%	41.1%	45.2%	49.3%	49.8%	51.3%	53.0%	54.0%	55.1%
03 BLOOD	85.7%	85.7%	87.5%	88.9%	90.0%	82.4%	66.7%	62.5%	66.7%	63.9%	63.6%	61.7%	60.4%	55.6%	46.0%
04 IMMUN	58.3%	66.7%	57.1%	62.5%	52.6%	46.2%	41.4%	32.1%	32.3%	33.3%	30.0%	28.0%	37.5%	38.5%	40.7%
05 METAB	62.8%	59.2%	57.5%	59.6%	52.9%	54.1%	52.1%	49.3%	53.2%	54.3%	52.3%	49.5%	50.5%	47.9%	45.7%
06 NEURO	59.1%	51.4%	48.2%	38.0%	32.1%	29.0%	26.1%	23.9%	25.2%	25.0%	29.8%	30.2%	31.8%	34.1%	35.7%
07 VISAL	50.0%	50.0%	53.3%	55.6%	47.6%	45.5%	34.4%	34.4%	37.1%	28.6%	25.0%	21.7%	23.1%	28.3%	31.0%
08 CIRCU	50.0%	47.2%	44.4%	35.1%	33.9%	36.9%	43.6%	40.9%	36.1%	32.5%	31.4%	28.8%	31.3%	26.2%	20.4%
09 RESPR	62.5%	57.9%	60.0%	50.0%	46.4%	52.6%	52.4%	48.8%	45.7%	42.3%	42.1%	38.6%	40.4%	35.9%	34.0%

10 DIGST	47.4%	43.5%	38.5%	37.5%	41.2%	34.2%	32.6%	31.4%	32.1%	34.6%	33.3%	26.7%	29.0%	30.2%	31.2%
11 SKINS	58.8%	55.0%	42.1%	27.8%	25.0%	36.0%	41.4%	36.4%	37.8%	40.9%	40.0%	43.1%	47.2%	49.2%	52.6%
12 MUSKE	87.0%	81.5%	75.9%	66.7%	65.6%	62.5%	55.9%	55.9%	48.6%	47.1%	48.7%	44.7%	40.0%	43.1%	44.0%
13 GENIT	66.7%	60.0%	43.8%	31.6%	42.3%	41.4%	40.0%	37.9%	34.4%	38.9%	44.4%	34.2%	26.7%	25.0%	25.5%
14 OTHER	47.4%	54.6%	58.3%	46.4%	43.3%	39.4%	36.1%	25.7%	22.0%	16.0%	12.0%	16.2%	20.8%	18.7%	18.9%